Characterization of residual lipid-rich plaques despite achieving LDL-C <1.8mmol/l with a statin in patients with coronary artery disease: insights from the REASSURE-NIRS registry
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
27 August 2021
ESC Premium Access
Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study
27 August 2021
ESC Premium Access
Hospitalized patients with hypertension and moderate COVID-19 benefit from continuing ACEIs and ARBs: Insights from the BRACE CORONA trial